- Feb 13, 2021KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Feb. 13, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced the first presentation of new...
- Feb 2, 2021Companies launch neurology-focused incubator at Eisai's G2D2 facility in Cambridge, Mass.
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. and BioLabs announced today the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups aiming...
- Jan 29, 2021The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is June 7, 2021
CAMBRIDGE, Mass. and TOKYO, January 29, 2021 (GLOBE NEWSWIRE) – Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has...
- Jan 27, 2021Data include the first presentation of results from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) evaluating KEYTRUDA® (pembrolizumab) plus LENVIMA and LENVIMA plus everolimus
Eisai will present four abstracts at the virtual Genitourinary Cancers Symposium 2021 (#GU21) from February 11-13, 2021. These investigational data include a late-breaking oral presentation from...
- Jan 26, 2021HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been listed in the 2021 Global 100 Most Sustainable Corporations in the World (Global 100), a...
- Jan 20, 2021
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Dr. Richard Woodman as Chief Clinical Officer (CCLO) of its Oncology Business Group....
- Jan 11, 2021
Eisai will present five abstracts across four tumor types at the Gastrointestinal Cancers Symposium (#GI21), which is being held virtually from January 15-17, 2021. Investigational data on the...
- Dec 16, 2020First Overall Survival Analysis for KEYTRUDA Plus LENVIMA Combination in a Phase 3 Study in Advanced Endometrial Cancer
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Dec. 16, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the pivotal Phase 3...
- Dec 8, 2020Latest Initiative of #ThisIsMBC "Perseverance" to be Unveiled at the 2020 Virtual San Antonio Breast Cancer Symposium
Eisai Inc. and METAvivor today announced the launch of Perseverance, a new initiative of the #ThisIsMBC campaign. Perseverance showcases imagery of a diverse group of 12 participants capturing the...
- Dec 7, 2020Key data results:
Eisai Inc. presented 52-week seizure freedom data related to its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2020 American Epilepsy Society (AES) Annual Meeting virtual conference....
- Dec 1, 2020EMBARGOED UNTIL: 9:00 AM EST on December 4
Eisai Inc. announced today that new data on its antiepileptic drug FYCOMPA® (perampanel) CIII will be presented at the 74th American Epilepsy Society (AES) Annual Meeting to be held from December...
- Nov 20, 2020Results support 24 mg as the starting dose for LENVIMA in patients with radioactive iodine-refractory differentiated thyroid cancer
Eisai announced results from Study 211 evaluating the safety and efficacy of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, at two starting doses:...
- Nov 19, 2020Key findings reinforce safety and efficacy and dosing strategies of LENVIMA
Eisai announced today the presentation of three abstracts including investigational data in thyroid cancer and osteosarcoma at the European Society for Medical Oncology (ESMO) Asia Virtual...
- Nov 10, 2020LENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus Sunitinib
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., November 10, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new investigational data...
- Nov 7, 2020Study 218 compares 18 mg and 14 mg starting doses of LENVIMA plus 5 mg everolimus in patients with clear-cell RCC following prior anti-angiogenic therapy, with prior anti-PD-1/PD-L1 therapy permitted
Eisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of two different starting doses (18 mg versus 14 mg once daily) of LENVIMA, an orally available multiple...
- Nov 5, 2020Data includes an oral presentation on results from a Phase 2 trial evaluating starting doses of LENVIMA in combination with everolimus (LEN+EVE)
Eisai will present seven abstracts at the International Kidney Cancer Symposium (IKCS) 2020 from November 6-7, 2020. New investigational data from Study 218, a Phase 2 trial evaluating the safety...
- Nov 2, 2020Nine presentations will highlight Eisai's investigational novel therapies being studied to treat Alzheimer's disease and its clinical symptoms
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and research from the company's Alzheimer's disease (AD) pipeline, including...
- Oct 27, 2020AMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19
LOS ANGELES – (BUSINESS WIRE)--Global Coalition for Adaptive Research (LOS ANGELES, CA), Amgen (THOUSAND OAKS, CA), and Eisai Co., Ltd. (TOKYO, Japan “Eisai”) -- The Global Coalition for...
- Sep 30, 2020Eisai Continues MOMENTUM 2 Expanded Access Program (Study 405) for Patients Previously Prescribed Lorcaserin to Treat Dravet and Other Refractory Epilepsies
Eisai Inc. announced today that, after consulting with the U.S. Food and Drug Administration (FDA), the Company has initiated a Phase 3 clinical study, MOMENTUM 1 (Study 304, NCT number pending),...
- Sep 20, 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Sept. 20, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new investigational data from two...
- Sep 10, 2020Data to include key findings from the LEAP (LEnvatinib And Pembrolizumab) clinical trial program evaluating the combination across multiple cancers including melanoma, non-small cell lung cancer (NSCLC) and six new tumor types
Eisai will present two late breakers and 10 e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21, 2020. Notable data from ongoing LEAP clinical...
- Aug 28, 2020New analyses of long-term data explores the efficacy and safety of DAYVIGO over 12 months among adults ages 65 and older and in perimenopausal women as well as fatigue severity
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced findings from several post hoc analyses of DAYVIGO™ from the Phase 3 SUNRISE 1 and 2 clinical studies and...
- Aug 24, 2020Nine presentations, including a long-term efficacy and safety analysis of DAYVIGO in adults ages 65 and older and interim results from a pilot study on the transition from zolpidem to DAYVIGO, to be shared at the meeting
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will present new DAYVIGO™ (lemborexant) CIV research at the SLEEP 2020 virtual conference, the 34th annual...
- Aug 11, 2020- Focusing in Scientific Innovation and Collaboration in Oncology, Alzheimer's disease and other Neurological Disorders
Eisai Inc., an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., (based in Tokyo, Japan) announced today the relocation of its New Jersey-based...
- Aug 11, 2020
Eisai Inc. announced today the topline results from Study 211, a Phase 2 trial evaluating the efficacy and safety of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor...
Copyright © Eisai Inc. 2021
|
All Rights Reserved
